The Davis Companies is planning to construct a three-story, 161,616-rsf research facility in Cambridge, Mass. Strategically sited in a new life sciences cluster called The Quad, the purpose-built structure will provide Class A lab and office environments for biomedical and pharmaceutical firms. Features of 101 Smith Place include:
Moderna is partnering with Alexandria Real Estate Equities to create a 462,000-rsf headquarters and research facility at the Alexandria Center development at One Kendall Square. Accelerating the discovery and development of mRNA vaccines and therapeutics, the collaborative structure will feature leading-edge R&D labs, sophisticated offices, and engaging gathering spaces.
AstraZeneca is planning to construct a $360 million manufacturing center in the Blanchardstown region of Dublin. Located on the Alexion Campus in College Park, the next-generation facility will leverage advanced process technologies and digital innovation solutions to produce small-molecule APIs (active pharmaceutical ingredients). Significantly reducing commercialization lead times, the sustainably designed structure will integrate lean manufacturing practices to lower operating costs and reduce carbon emissions.
Tonix Pharmaceuticals broke ground in August of 2021 on the 45,000-sf Advanced Development Center in Dartmouth, Mass. Enabling the production of clinical-stage vaccines for COVID-19 and other infectious diseases, the BSL-2 facility will utilize single-use bioreactors and purification suites for optimal efficiency and flexibility. The cGMP center will also offer state-of-the-art research, development, and analytical suites. Approximately 70 scientists, technicians, and manufacturing staff will work in the turnkey building.
Ivanhoé Cambridge and Lendlease will break ground in summer of 2022 on a 320,000-sf life sciences facility in Boston. Designed by SGA, the nine-story building will provide state-of-the-art labs, offices, and collaboration spaces for biomedical and pharmaceutical tenants. Offering BSL-1 and BSL-2 research environments, the amenity-rich structure will include a multipurpose ground floor, a parking garage, and numerous outdoor areas.
The Fitzsimons Innovation Community broke ground in August of 2021 on Bioscience 5 in Aurora, Colo. Strategically located next to the University of Colorado Anschutz Medical Campus, the 90,000-sf building will enable biomedical and pharmaceutical tenants to manufacture next-generation cell and gene therapy products on a commercial scale. Saunders Construction is the general contractor for the highly flexible facility, which is slated for occupancy in spring of 2022.
The Davis Companies and Boston Development Group broke ground in August of 2021 on a purpose-built life sciences building in Watertown, Mass. The joint-venture project will offer 224,000 rsf of Class A research space for biomedical and pharmaceutical tenants. Designed by Elkus Manfredi Architects, the facility will provide next-generation laboratories, offices, a fitness center, a shared rooftop balcony, six private outdoor areas, and ample indoor parking accessible directly beneath the building.
Precision NanoSystems is constructing its global headquarters in Vancouver, British Columbia. Located in the four-story Evolution Block building, the 75,000-sf leased facility will feature a GMP biomanufacturing center for the production of genetic medicines and RNA-based therapeutics. The federal government has contributed CAD$25.1 million in funding towards the project's construction to increase the nation's domestic supply of COVID-19 vaccines and prepare for future pandemics.
Landmark Bio began construction in July of 2021 on a leased facility in Watertown, Mass. Supported by $76 million in funding, the 40,000-sf project will accelerate the availability of novel therapeutics by collocating research, development, manufacturing, and commercialization activities in the same structure. Featuring eight GMP cleanrooms configured to allow production of both cell and viral vector materials, the center will include labs, offices, and quality control suites.
The Ohio State University is constructing the $237.5 million Interdisciplinary Research Facility in Columbus. Anchoring a new innovation district, the 305,000-sf building will accommodate biomedical, life sciences, engineering, and environmental science research programs. Designed by Pelli Clarke & Partners and Moody Nolan to foster interaction and collaboration, the five-story structure will provide wet labs, computational labs, core labs, a vivarium, and a variety of support spaces.
Boston Properties broke ground in July of 2021 on a $105 million life sciences facility in Waltham, Mass. Designed by Stantec, 180 CityPoint will provide leasable lab and office environments with exceptional access to natural light and views. Featuring shared meeting spaces and a collaborative co-working nexus, the six-story, 329,000-sf building will include an expansive roof deck, a food hall, a wellness center, an indoor basketball court, and a 900-car parking structure.
Nexus Pharmaceuticals opened a $100 million manufacturing facility in July of 2021 in Pleasant Prairie, Wis. Increasing the nation's domestic supply of life-saving medicines, the 84,000-sf structure will produce specialty and generic injectable drugs, including vaccines for COVID-19 and other infectious diseases. The three-story building features an advanced isolator system and multiple lyophilization machines to ensure maximum product protection and sterility.
MiraCosta Community College is planning to construct a 23,000-sf chemistry and biotechnology building in Oceanside, Calif. The $46.9 million project, crafted through a design-build partnership between HED and C.W. Driver, will provide leading-edge environments for the school's growing biotechnology program and other STEM courses in science, technology, engineering, and mathematics. Featuring flexible, 40-person classrooms, the facility will offer a vibrant mix of instructional, work, social, and laboratory spaces.
DivcoWest broke ground in June of 2021 on a 375,000-sf life sciences facility in the Cambridge Crossing innovation district. Designed by Ennead Architects with Jacobs Consultancy as the architect of record, the collaborative building will provide leading-edge research environments for biomedical and pharmaceutical tenants. Comprising ten floors of lab space, two penthouse levels, and multiple outdoor terraces, the project will offer generous ceiling heights with minimal interior columns for optimal flexibility.
AbCellera Biologics is planning to break ground in late 2021 on a manufacturing plant for therapeutic antibodies in Vancouver, British Columbia. Supported by $175.6 million in federal funding, the 130,000-sf project will cost approximately CAD$240 million to build. Offering advanced production suites, labs, offices, and warehouse space, the GMP facility will enhance the country's ability to create vaccines in response to future pandemic threats.
